ClinicalTrials.gg
CompletedNCT02571855Updated Jul 10, 2018

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of ACT-541468 in Healthy Young Adults and Elderly Subjects

A Phase 1 interventional study of ACT-541468 (hydrochloride salt) and ACT-541468 (free base) in Healthy Subjects, sponsored by Idorsia Pharmaceuticals Ltd.. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-07-10.

Sponsored by Idorsia Pharmaceuticals Ltd. · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
85
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies testing daridorexant in Sleep Initiation and Maintenance Disorders — 6 open to participants now, 6 under way, none of them phase 3. daridorexant · Sleep Initiation and Maintenance Disorders.

Enrollment
12th of 16
85 · median 165
Started
2015
the only one that year
Phase 1
Only one
of the 16
Registered
1st of 16
by date
Lead sponsor
8 of 16
Idorsia Pharmaceuticals Ltd.

Among the 16 studies testing daridorexant in Sleep Initiation and Maintenance Disorders, this one is the 12th largest by enrollment, is the only one that started in 2015, is the only one in phase 1, and was the 1st registered.

Sleep Initiation and Maintenance Disorders

2,729 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 730 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

6 of the 16 studies testing daridorexant in Sleep Initiation and Maintenance Disorders are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About daridorexant

daridorexant: first FDA approval 2022 (QUVIVIQ), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 389 Sleep Initiation and Maintenance Disorders studies recruiting now, 152 (39%) set no upper age limit and 207 (53%) stop at 75 or younger; 59 take children under 18; 108 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing daridorexant in Sleep Initiation and Maintenance Disorders, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the tolerability, safety, pharmacokinetics (PK, or amount of drug over time in the body) and pharmacodynamics (PD, or effects on the body) of ACT-541468 following multiple ascending doses in healthy adults and following single ascending doses in healthy elderly subjects when administered in the morning. The safety, PK and PD of ACT-541468 will also be assessed after repeated evening administration of a selected dose in both healthy adults and elderly.

Read the detailed description

In the first-in-man study, single doses of ACT-541468 administered in healthy young adults were well tolerated up to the dose level of 200 mg (inclusive) and yielded results compatible with possible sleep facilitating effects of ACT-541468. So the present study aimed to further investigate the effects of ACT-541468 after multiple ascending doses in healthy young subjects as well as after single ascending doses in elderly subjects (morning administrations). The effects of repeated administrations of a selected dose administered in the evening in both healthy adults and elderly, will also be investigated.

03

Conditions studied

  • Healthy Subjects

Keywords

  • insomnia
  • Pharmacokinetics
  • Safety
  • Pharmacodynamics
  • Healthy
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Signed .
  • Adults aged from 18 to 45 years (inclusive) for Part A; elderly aged from 65 to 80 years (inclusive) for Part B; both adults from 18 to 45 years and elderly from 65 to 80 years (inclusive) for Part C.
  • Regular sleep pattern of at least 6 hours nocturnal sleep.
  • Young females must have negative pregnancy tests at screening and at pre-dose on Day 1 and use a reliable method of
  • (BMI) between 18.0 and 30.0 kg/m2 (inclusive) at screening.
  • Systolic blood pressure (SBP), diastolic blood pressure (DBP) and pulse rate (PR) between 100-145 mmHg, 50-90 mmHg and 45-90 bpm (all inclusive) for young adults, respectively; SBP, DBP and PR between 100-160 mmHg, 50-95 mmHg and 45-100 bpm (all inclusive) for elderly, respectively.
  • Healthy on the basis of physical examination, and laboratory tests.

Exclusion Criteria:

Principal exclusion criteria common to young adults and elderly:

  • Pregnant or lactating women.
  • Any to the study drugs.
  • History or presence of any disease or condition or treatment, which may put the subject at risk of participation in the study or may interfere with the absorption, distribution, metabolism or excretion of the study drugs.
  • History of narcolepsy or cataplexy or modified Swiss narcolepsy scale total score \< 0 at screening.
  • Any circumstances or conditions, which, in the opinion of the investigator, may affect the subject's full participation in the study or compliance with the protocol.

Exclusion criteria for young adults only:

  • Treatment with any prescribed medications or over-the-counter medications within 2 weeks prior to study drug administration.

Exclusion criteria for elderly only:

  • Previous chronic treatment with any medication that is not given in stable doses and/or stable regimen within 2 months prior to screening.
  • Previous treatment with CNS-active drugs or within 2 months prior to screening.
  • Treatment with inhibitors of (e.g., azole derivatives, ritonavir, clarithromycin) from 2 weeks prior to screening visit and up to EOS.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
85 participants (actual)

Study arms

  • Experimental
    Part A: ACT-541468 multiple ascending doses

    Six young adults will receive ACT-541468 in the morning from Day 1 to Day 5 at each dose level in a sequential manner (total number of subjects = 18). Planned dose levels are 10, 25 and 75 mg per day

    Drug: ACT-541468 (hydrochloride salt)

  • Placebo comparator
    Part A: Placebo

    For each ACT-541468 dose level tested in Part A, 2 young adults will receive matching placebo in the same conditions (total number of subjects = 6)

    Drug: Placebo

  • Experimental
    Part B: ACT-541468 single ascending doses

    Six elderly will receive ACT-541468 in the morning of Day 1 at each dose level in a sequential manner (total number of subjects = 18). Planned dose levels are 5, 15 and 25 mg

    Drug: ACT-541468 (hydrochloride salt)

  • Placebo comparator
    Part B: Placebo

    For each ACT-541468 dose level tested in Part B, 2 elderly will receive matching placebo in the same conditions (total number of subjects = 6)

    Drug: Placebo

  • Experimental
    Part C: repeated dose of ACT-541468

    Sixteen young adults and eight elderly will receive ACT-541468 (planned dose: 25 mg) in the evening for 7 days (8 days for 6 of the 16 young adults).

    Drug: ACT-541468 (free base)

  • Placebo comparator
    Part C: Placebo

    Four young adults and 2 elderly will receive matching placebo in the same conditions as subjects receiving the active compound in Part C

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Number of participants with Adverse Events (AEs)

    Treatment emergent adverse events and treatment emergent serious adverse events will be evaluated throughout the study

    Time frame: up to 72 hours post dosing

  2. Changes from baseline in ECG variables and vital signs (heart rate and blood pressure)

    12-lead electrocardiogram variables including RR, PR, QRS, QT and QTc intervals at scheduled time points during Parts A, B and C

    Time frame: up to 72 hours post dosing

  3. Changes from baseline in clinical laboratory parameters

    Laboratory tests including hematology, blood chemistry and urinalysis at scheduled time points during PArts A, B and C

    Time frame: up to 72 hours post dosing

Secondary outcomes

  1. Maximum plasma concentration (Cmax) of ACT-541468 after daytime and bedtime intake

    Cmax will be determined after single (Parts A and B) and multiple morning doses (Part A) as well as after repeated evening doses to identify the nighttime PK profile (Part C)

    Time frame: Part A: Day 1 and Day 5; Part B: Day 1; Part C: evening of Day 8 (pre-dose) and Day 9 (nighttime samples)

  2. Time to reach Cmax (tmax) of ACT-541468 after daytime and bedtime intake

    tmax will be determined after single (Parts A and B) and multiple morning doses (Part A) as well as after repeated evening doses to identify the nighttime PK profile (Part C)

    Time frame: Part A: Day 1 and Day 5; Part B: Day 1; Part C: evening of Day 8 (pre-dose) and Day 9 (nighttime samples)

  3. Terminal half-life [t(1/2)] after daytime and bedtime intake

    t(1/2) will be determined after single (Parts A and B) and multiple morning doses (Part A) as well as after repeated evening doses (Part C)

    Time frame: Part A: Days 1 and 5, from pre-dose up to 72 h post-dose; Part B: Day 1, at pre-dose up to 72 h post-dose; Part C: from the morning of Day 8 up to 60 h post-dose and from the evening of Day 8 (pre-dose) until 36 h post-dose (with nighttime samples)

  4. Areas under the plasma concentration-time curves [AUC(0-8), AUC(0-24)] of ACT-541468 after daytime and bedtime intake

    AUC from time 0 to 8 hours after study drug administration \[AUC(0--8)\] and from time 0 to 24 hours after study drug administration \[AUC(0--24)\] will be determined after single (parts A and B) and multiple morning doses (Part A) as well as after multiple evening doses (Part C)

    Time frame: Part A: Days 1 and 5, from pre-dose up to 72 h post-dose; Part B: Day 1, at pre-dose up to 72 h post-dose; Part C: from the morning of Day 8 up to 60 h post-dose and from the evening of Day 8 (pre-dose) until 36 h post-dose (with nighttime samples)

  5. Areas under the plasma concentration-time curves [AUC(0-t), AUC(0-inf)] of ACT-541468 after daytime and bedtime intake

    AUC from time 0 to infinity \[AUC(0--inf\], AUC from time 0 to time of the last measured concentration above the limit of quantification \[AUC(0--t)\] will be determined after single (Part B) and multiple morning doses (Part A) as well as after multiple evening doses (Part C)

    Time frame: Part A: Day 5, from pre-dose up to 72 h post-dose; Part B: Day 1, at pre-dose up to 72 h post-dose; Part C: from the morning of Day 8 up to 60 h post-dose and from the evening of Day 8 (pre-dose) until 36 h post-dose (with nighttime samples)

  6. Sedation as measured by saccadic peak velocity

    saccadic eye movements (SEM) will be recorded by electrooculography and the average values of saccadic peak velocity of the SEM will be used as parameter of sedation

    Time frame: Part A: Day 1 and Day 5; Part B: Day 1; Part C: Day 2 and Day 14

  7. Visual motor coordination

    Visual motor coordination will be assessed with the adaptive tracking test and the average tracking performance will be used as parameter of coordination

    Time frame: Part A: Day 1 and Day 5; Part B: Day 1; Part C: Day 2 and Day 14

  8. Change from baseline in body sway

    Body sway will be assessed using a body sway meter

    Time frame: Part A: Day 1 and Day 5; Part B: Day 1; Part C: Day 2 and Day 14

  9. Change from baseline in subjective cognitive effects

    Subjects will rate sleepiness, alertness and mood using questionnaires

    Time frame: Part A: every day from Day 1 to Day 6; Part B: Day 1; Part C: Day 1 to Day 8

07

Study locations

1 site
  • Investigator Site
    Leiden, Netherlands
08

References and documents

Publications

  • Muehlan C, Boehler M, Brooks S, Zuiker R, van Gerven J, Dingemanse J. Clinical pharmacology of the dual orexin receptor antagonist ACT-541468 in elderly subjects: Exploration of pharmacokinetics, pharmacodynamics and tolerability following single-dose morning and repeated-dose evening administration. J Psychopharmacol. 2020 Mar;34(3):326-335. doi: 10.1177/0269881119882854. Epub 2019 Oct 23. PubMed 31642731 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2015 to primary completion in Feb 2016, 4 months.

Of 23 industry-sponsored phase 1 interventional studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 4 months of starting (the median); a quarter within 1 and three quarters within 5. This study's 4 months is close to that.

Counting every sponsor, half of 39 studies reached it within 5 months; a quarter within 3 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2015
First posted
Oct 8, 2015
StartActual
Oct 1, 2015
Primary completionActual
Feb 1, 2016
CompletionActual
Feb 1, 2016
Last update
Jul 10, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02571855
Responsible party
Sponsor
First posted
Oct 8, 2015
Start date
Oct 1, 2015
Primary completion
Feb 1, 2016
Completion
Feb 1, 2016
Last update
Jul 10, 2018

Study contacts

Clemens Mühlan, MSc
study director · Actelion

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Daridorexant

Start the discussion